View Older Stories View More Recent Stories

Apr 9, 2019 03:57PM FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Apr 7, 2019 05:00AM Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe
Mar 20, 2019 08:33AM Amgen (AMGN) Cytokinetics, Inc. (CYTK) and Servier Report Continuation Of GALACTIC-HF Following Planned Interim Analysis
Mar 20, 2019 08:30AM Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Mar 20, 2019 08:30AM Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Mar 15, 2019 04:01PM Amgen (AMGN) Announces New 4-Year Outcomes Study to Examine Long-Term Effects Of Repatha In High-Risk CVD Patients Without Prior Heart Attack Or Stroke
Mar 15, 2019 04:00PM Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
Mar 12, 2019 09:29AM Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk
Mar 7, 2019 04:05PM Amgen Announces 2019 Second Quarter Dividend
Mar 7, 2019 04:00PM Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference
Mar 6, 2019 04:00PM New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations
Feb 28, 2019 04:00PM Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019
Feb 25, 2019 04:58PM Amgen (AMGN) Confirms Jury Upholds Its Patents on Repatha
Feb 25, 2019 04:56PM Jury Upholds Amgen's Patents On Repatha® (evolocumab)
Feb 25, 2019 08:05AM Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
Feb 25, 2019 08:05AM Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
Feb 21, 2019 08:37AM Amgen (AMGN) Cytokinetics (CYTK) & Servier Report Start of METEORIC-HF, the Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients with Heart Failure
Feb 21, 2019 08:30AM Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Feb 21, 2019 08:30AM Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Jan 29, 2019 04:01PM Amgen Reports Fourth Quarter And Full Year 2018 Financial Results
Jan 24, 2019 04:30PM Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results
Jan 24, 2019 04:00PM Amgen (AMGN) Receives NMPA Approval For Repatha in China
Jan 24, 2019 04:00PM Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events
Jan 24, 2019 09:03AM Amgen (AMGN), Allergan (AGN) Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Jan 24, 2019 09:00AM Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Jan 22, 2019 09:03AM Amgen (AMGN) Announces EC Approves BLINCYTO in Patients With Philadelphia Chromosome Negative MRD-Positive B-cell Precursor ALL
Jan 22, 2019 09:00AM European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Jan 16, 2019 05:44PM Amgen (AMGN), UCB Confirm Positive Vote From FDA Panel in Favor of Approval for EVENITY (romosozumab)
Jan 16, 2019 05:41PM Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)
Jan 8, 2019 04:01PM Amgen (AMGN), ECB Announce EVENITY Received Approval In Japan For Treatment of Osteoporosis
Jan 8, 2019 04:00PM EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Jan 7, 2019 04:01PM Amgen (AMGN) Announces Plan to Make All Repatha Device Options Available In US at 60 Percent Reduced List Price
Jan 7, 2019 04:00PM Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
Jan 3, 2019 04:00PM Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference
Dec 19, 2018 04:01PM Amgen (AMGN) Reports Submission of Supplemental Biologics License Application for Nplate (romiplostim)
Dec 19, 2018 04:00PM Amgen Submits Supplemental Biologics License Application For Nplate® (romiplostim)
Dec 18, 2018 11:00PM Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology
Dec 18, 2018 04:00PM Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners
Dec 17, 2018 09:02AM Amgen (AMGN) Submits BLA for ABP 710 to US Food And Drug Administration
Dec 17, 2018 09:00AM Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Dec 14, 2018 04:00PM Amgen (AMGN) Announces FDA Approves Nplate For Use In Pediatric Patients With Immune Thrombocytopenia
Dec 14, 2018 04:00PM FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
Dec 13, 2018 04:00PM Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries
Dec 11, 2018 04:04PM Amgen (AMGN), Magellan Rx Management Announce Collaboration to Improve Patient Care For Chronic, Difficult-to-Treat Conditions
Dec 11, 2018 04:00PM Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions
Dec 10, 2018 04:41PM Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials
Dec 7, 2018 04:00PM Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend
Dec 3, 2018 09:15PM Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Dec 3, 2018 04:00PM Amgen To Present At The Citi Global Healthcare Conference
Nov 30, 2018 04:00PM Amgen (AMGN), UCB Announce FDA Advisory Committee Meeting To Review EVENITY
View More Recent Stories View Older Stories